Foghorn Therapeutics (FHTX) Enterprise Value (2019 - 2026)

Foghorn Therapeutics' Enterprise Value history runs 8 years deep, the most recent figure standing at -$88.9 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 45.7% year-over-year to -$88.9 million in Q1 2026; TTM through Mar 2026 was -$88.9 million, a 45.7% decrease from a year earlier, with the FY2025 full-year figure at -$82.1 million, down 48.1% from the prior year.
• Enterprise Value fell to -$88.9 million in Q1 2026 per FHTX's latest filing, from -$82.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$50.6 million in Q1 2023 and bottomed at -$213.6 million in Q1 2022.
• The 5-year median for Enterprise Value is -$73.8 million (2025), against an average of -$82.4 million.
• Across the five-year window, Enterprise Value plunged 221.52% in 2022 and soared 76.3% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$52.2 million in 2022, then sank by 53.86% to -$80.3 million in 2023, then surged by 30.97% to -$55.5 million in 2024, then slumped by 48.1% to -$82.1 million in 2025, then dropped by 8.26% to -$88.9 million in 2026.
• Per Business Quant, the three latest FHTX Enterprise Value figures stand at -$88.9 million (Q1 2026), -$82.1 million (Q4 2025), and -$90.6 million (Q3 2025).